Published in final edited form as:

Expert Opin Ther Targets. 2016 August ; 20(8): 935–945. doi:10.1517/14728222.2016.1151003.

Lysyl Oxidase Isoforms and Potential Therapeutic Opportunities for Fibrosis and Cancer

Philip C. Trackman

Department of Molecular and Cell Biology, Boston University, Henry M. Goldman School of Dental Medicine, Boston, MA 02118, Telephone: (617) 638-4076

Philip C. Trackman: trackman@bu.edu

Abstract

Introduction—The lysyl oxidase family of enzymes is classically known as being required for connective tissue maturation by oxidizing lysine residues in elastin and lysine and hydroxylysine residues in collagen precursors. The resulting aldehydes then participate in cross-link formation, which is required for normal connective tissue integrity. These enzymes have biological functions that extend beyond this fundamental biosynthetic role, with contributions to angiogenesis, cell proliferation, and cell differentiation. Dysregulation of lysyl oxidases occurs in multiple pathologies including fibrosis, primary and metastatic cancers, and complications of diabetes in a variety of tissues.

Areas covered—This review summarizes the major findings of novel roles for lysyl oxidases in pathologies, and highlights some of the potential therapeutic approaches that are in development and which stem from these new findings.

Expert opinion—Fundamental questions remain regarding the mechanisms of novel biological functions of this family of proteins, and regarding functions that are independent of their catalytic enzyme activity. However, progress is underway in the development of isoform-specific pharmacologic inhibitors, potential therapeutic antibodies and gaining an increased understanding of both tumor suppressor and metastasis promotion activities. Ultimately, this is likely to lead to novel therapeutic agents.

Keywords

cancer; copper amine oxidases; fibrosis; lysyl oxidase propeptide; lysyl oxidases; lysyl tyrosylquinone

1. Introduction

The well-established functions of lysyl oxidases are to catalyze the final enzyme reaction required for biosynthetic cross-linking of collagens and elastin¹. Studies over the last 15

Correspondence to: Philip C. Trackman, trackman@bu.edu.

Financial and competing interests disclosure: The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

years, however, have identified a variety of additional biological activities including keratinocyte ^{2, 3} and chondrocyte differentiation ⁴, tumor growth inhibition ^{5, 6}, promotion of metastasis in cancer ⁷, stimulation of cell proliferation ⁸, cell migration ⁹, angiogenesis ¹⁰, and extracellular matrix maturation ¹¹. Understanding the biology and mechanisms of all functions of each lysyl oxidase isoform is likely to provide significant therapeutic opportunities in addressing both cancer and fibrosis. This review is focused on fibrosis and cancer, and particularly highlights novel mechanistic relationships that extend beyond the known functions of lysyl oxidases in collagen biosynthesis.

2. Body

The lysyl oxidase family consists of five members in mammals designated lysyl oxidase (LOX) and lysyl oxidase like-1 through lysyl oxidase like-4 (LOXL1 - LOXL4). All five members have a conserved C-terminal domain that contains the active enzyme region, and a more variable N-terminal pro-region. All members have a signal peptide and are secreted into the extracellular environment. LOX and LOXL1 both undergo extracellular proteolytic processing by procollagen C-proteinases ^{12, 13}, while it is unclear whether or not LOXL2 – LOXL4 require processing for activation ¹⁴. LOXL2 – LOXL4 is a sub-group within the family based on the common feature of their propeptide domains which all contain four scavenger receptor cysteine rich domains which are not present in LOX or LOXL1 ^{15, 16}. The functions of the pro-regions of LOXL2 – LOXL4 are currently unknown. The propeptide domain of LOX, known as LOX-PP, has tumor growth inhibitory properties that will be reviewed in detail below. The pro-region of LOXL1 appears to help with its own trafficking and activation by procollagen C-proteinase ¹⁷.

All lysyl oxidase isoforms incorporate copper intracellularly, likely dependent on the copper chaperone ATP7a ¹⁸. Copper binding is dependent on conserved amino acid residues in the active site in LOX ^{19, 20}, and copper incorporation is required for optimal lysyl oxidase enzyme activity ²¹. All five isoforms have a conserved tyrosine and lysine residue which in LOX becomes the active site carbonyl cofactor lysyl tyrosyl quinone (LTQ). This cofactor is required for lysyl oxidase oxidation of its primary amine substrates: the epsilon amino group of lysine or hydroxylysine residues in collagens and lysine residues in elastin ^{22, 23}. By analogy to serum amine oxidases, copper is required for biogenesis of the LTQ cofactor, and this conversion does not appear to require a different enzyme protein for LTQ generation ²³⁻²⁵. In support, copper-binding residues were experimentally identified by site-directed mutagenesis loss of function studies of recombinant mouse LOX in which histidine residues 292, 294, and 296 were found to be required for LTQ generation in mouse LOX. Thus, a major function of copper bound in LOX is LTQ cofactor generation, which is a spontaneous auto-catalyzed post-translational modification required for ultimate acquisition of enzyme activity. In addition, it has been suggested that copper may have a role in stabilizing the structure of LOX ²¹, though this has not been directly evaluated.

The catalytic mechanism of the LOX reaction has been reviewed previously ²⁶ and is presented in Figure 1. Noteworthy is the requirement of Schiff base formation with the LTQ cofactor in the first step, which then facilitates the required redox reaction ²⁶. This reaction mechanism is the same as that which is known for other copper-dependent quinone

containing amine oxidases which catalyze oxidative deamination of primary amines and for which considerable experimental evidence in support also exists²⁷⁻²⁹. It is notable that secondary and tertiary amines have been shown not to function as substrates for lysyl oxidase and are not oxidized³⁰ likely because Schiff base formation cannot occur.

2.1 Activities of each lysyl oxidase isoform and potential therapeutic opportunities

2.1.1 Lysyl oxidase (LOX)—Lysyl oxidase (LOX) may be the best studied isoform to date and was the first one cloned^{31,32}. It is synthesized as a 50 kDa pre-proenzyme and like all five isoforms undergoes signal peptide removal and intracellular N-glycosylation in the endoplasmic reticulum. The 50 kDa LOX proenzyme is secreted into the extracellular environment as an inactive precursor³³. Pro-LOX then undergoes proteolytic processing by procollagen C-proteinases which are products of the *BMP1*, *TLL1* and *TLL2* genes^{12,13}. This processing releases the active enzyme and the lysyl oxidase propeptide LOX-PP. Active LOX and LOX-PP each have independent biological activities.

2.1.1.1 Active LOX biological activities: Lysyl oxidase (LOX) is the most abundantly expressed isoform in most, but not all tissues³⁴⁻³⁶. As noted, LOX is required for the biosynthesis of normal collagens and elastin, and therefore LOX is critical for vascular, mineralized and non-mineralized connective tissues. LOX knockout mice exhibit perinatal death due to vascular and cardiovascular defects^{37,38}. In fibrotic disease, elevated lysyl oxidase activity is consistently observed and contributes to resistance of the extracellular matrix to proteolytic degradation, thereby contributing to connective tissue accumulation and fibrosis (reviewed in³⁹). Some recent studies of fibrosis have included a comprehensive analysis of LOX isoforms expression, while other studies have focused on LOX activity without assessing for the genetic source, or assessed for LOX expression only, or only by inhibition by β -aminopropionitrile (BAPN) which inhibits all five isoforms⁴⁰⁻⁴⁸. Although some reports may suggest that BAPN is inactive against some LOX isoforms in vivo, it should be understood that BAPN can serve as a substrate for some serum amine oxidases which do not belong to the LOX family. Thus, if BAPN appears to not inhibit a LOX isoform in vivo, then it is likely that (1) either BAPN has been metabolized, or (2) that the activity in question occurs as a result of a non-enzymatic function of LOX or LOX isoform. Data consistently show LOX up-regulated in a variety of fibrotic conditions, sometimes accompanied by additional LOX isoforms, including lung-⁴⁹⁻⁵³, liver-^{43,54-56}, and heart-^{57,58}, and skin-⁵⁹⁻⁶¹ fibrosis, and hypertension^{47,58}. One notable exception is phenytoin-induced gingival overgrowth which appears to be accompanied by LOXL2 elevations and not LOX^{62,63}. Thus, tissue-specific regulation of different LOX isoforms in fibrosis and other related pathologies can occur and should be carefully monitored which may ultimately aid in developing therapeutic strategies.

Recent studies have identified an important and novel role for LOX enzyme activity in the development of myelofibrosis that extends beyond its role in collagen cross-linking. LOX expression is high early in megakaryocyte differentiation and its expression and enzyme activity is required for optimal PDGF signaling and cell proliferation. Decreased LOX expression with time permits appears to slow proliferation to permit differentiation of megakaryocytes to platelets. The GATA-1 low mouse is a model of myelofibrosis, and a

high level of LOX expression was found which results in extracellular matrix accumulation and bone marrow fibrosis. Inhibition of LOX activity with BAPN resulted in attenuation of myelofibrosis ⁶⁴. Thus, excess LOX activity in the bone marrow is a major contributor to myelofibrosis. Myeloproliferative neoplasms often result in bone marrow fibrosis, and assessments of expression of LOX isoforms in human myeloproliferative neoplasms was recently reported. Primary myelofibrosis is accompanied by clearly elevated expressions of 4 of the 5 LOX isoforms studies (LOXL4 was not studied), while some variation in elevated isoforms expression was observed in other myeloproliferative neoplasms ⁶⁵. Taken together, these studies point to inhibitors of LOX isoforms as a potential therapeutic strategy to treat myelofibrosis emanating from a variety of myeloproliferative neoplasms.

LOX-PP may also be involved in regulating the differentiation of megakaryocytes into platelets. rLOX-PP inhibits endomitosis and polyploidy of megakaryocytes by inhibiting TPO-stimulated ERK1/2 signaling which is required for differentiation into platelets ⁶⁶. Thus, high early LOX expression and enzyme activity promotes megakaryocyte accumulation via enhancing PDGF signaling and cell proliferation while correspondingly expressed LOX-PP inhibits polyploidy. In summary, data taken together suggest that as megakaryocytes differentiate into platelets, LOX down-regulation drives lower cell proliferation (via lower enzyme activity) and permits polyploidy (via lower LOX-PP levels).

Diabetic retinopathy is a major cause of blindness in aging subjects and in diabetic individuals. This condition is accompanied by perivascular cell death ⁶⁷ and basement membrane thickening and an acellular fibrotic lesion. Increased basement membrane thickening is associated with increased vascular permeability leading to bleeding and blindness ^{68, 69}. Increased expression of LOX has been associated with increased basement membrane thickening and permeabilization ⁷⁰. This is thought to be caused by uneven cross-linking of the basement membrane and distortion of its structure, leading to increased permeability of retinal capillaries. Elevated LOX and LOXL2 levels and inhibition of choroid neovascularization in vivo with neutralizing anti-LOX and – LOXL2 antibodies further supports functional contributions of LOX and LOXL2 to diabetic retinopathy ⁷¹.

There is now great interest in observations that elevated LOX expression accompanies and may drive metastatic cancer ^{7, 9, 72-78}. At least three ideas have emerged which are related to contributing mechanisms. Displastic tissues are characterized by fibrosis and increased tissue stiffness that can enhance cell migration. LOX-dependent collagen cross-linking increases stiffness, enhances fibrosis and integrin signaling, and thereby can create a permissive environment for tumor cell migration and intravasation ^{73, 79}. Some studies support the notion that, in addition, LOX promotes the formation of a metastatic niche at distant sites. In this model LOX is seen to localize at a distant site and then serves to attract tumor cells to extravasate. LOX has also been linked to promoting angiogenesis in tumors ⁸⁰. Although there is now little doubt that LOX activity contributes to metastasis, some aspects of some of studies related to LOX and metastatic niche identify the molecular size of LOX as 70 – 80 kDa ^{72, 81, 82}, while pro-lysyl oxidase is well-established to be a 48 – 50 kDa protein. This and other biochemical aspects of the study of LOX biology and chemistry should be carefully re-examined. If indeed LOX is somehow structurally modified

to result in a higher apparent molecular weight in some cancers, these modifications could be of significant biological consequence.

2.1.1.2. Lysyl oxidase propeptide (LOX-PP): The studies on active LOX and cancer summarized above are in contrast to early studies which indicated that LOX expression is reduced in tumor cell lines, and that LOX re-expression is required for stable phenotypic reversion of wildtype or mutant c-H-*ras*-expressing mouse and human cells⁸³⁻⁸⁷. This complexity is related to findings which demonstrate that stimulation of metastatic progression is dependent on active LOX enzyme, while LOX-PP inhibits Ras-signaling in vitro, and primary tumor growth in vivo^{5, 6, 88-90}. Thus, excess LOX activity emanating from all LOX isoforms has the potential to contribute to metastasis. Evidence that LOX-PP is a tumor suppressor as well as a tumor growth inhibitor comes from a study in which a polymorphism in the LOX-PP sequence resulted in a higher incidence of cancer in a subpopulation of triple-negative breast cancer patients⁹¹. As far as is known now, only LOX-PP which is unique in sequence, is a tumor growth inhibitor/tumor suppressor. No evidence exists that propeptides from the other four isoforms are tumor growth inhibitors. It is, therefore, of interest that LOXL2 and LOXL4 have been observed as highly up-regulated in metastatic cancers, and may be more effective promoters of metastatic disease than LOX possibly due to the absence of a tumor inhibiting domain⁹²⁻¹⁰⁵.

Several molecular targets of LOX-PP which mediate its inhibitory effects on tumor promoting signaling pathways have been identified in breast cancer and prostate cancer cell lines. Targets in prostate cancer cell lines include FGF-2 signaling mediated by FGFR1 and AKT activation^{106, 107}, and inhibition of DNA repair pathways mediated by binding to MRE11-containing DNA repair foci after nuclear localization¹⁰⁸. In breast cancer cells, targets are fibronectin-stimulated FAK signaling and ERK1/2 activation¹⁰⁹, inhibition of β -catenin activation by targeting the receptor-type protein tyrosine phosphatase kappa¹¹⁰, inhibition of Ras-signaling by direct targeting of Hsp70 and Raf leading to reduced ERK1/2 activation¹¹¹, inhibition of CIN-85-mediated invasion¹¹², and inhibition of proliferation and stimulation of apoptosis in vivo⁸⁸. An interesting study investigated the phenotype of a spontaneous mutation in the mouse *NNA1* transcription factor gene revealed ataxia caused by overexpression of LOX in Purkinje cells in the brain¹¹³. Purkinje cells are critical for development of normal neural networks in the brain. Effects of elevated LOX expression resulted in reduced Purkinje cell growth. This effect was shown not to be related to LOX enzyme activity, but instead directly depends on LOX-PP. LOX-PP was shown to inhibit the RelA subunit of NF- κ B from entering the nucleus, resulting in deficient mRNA and protein levels of MAP1B and MAP2 which are microtubule binding proteins required for Purkinje cell growth. Thus, in normal mice, normal NNA1 represses production of LOX. If LOX is overexpressed, LOX-PP then inhibits RelA nuclear localization leading to deficient MAP1B and MAP2 expression, deficient Purkinje cell production, contributing to ataxia. As noted above, LOX-PP targets many aspects of RAS signaling¹¹¹, and RAS can drive NF- κ B activation¹¹⁴. Thus, one possibility is that the primary molecular target of LOX-PP in this context could be RAF, though other RAS effectors are also possible.

LOX-PP is generated extracellularly by proteolytic processing by procollagen C-proteinases^{13, 33}. Molecular binding partners and targets of LOX-PP identified so far are

intracellular, except possibly cell surface FGFR1. Therefore, the pathways of LOX-PP cell uptake was investigated in a variety of cell lines to assess for possible avenues to enhance uptake and therefore potentially block cancer cell growth and metastatic potential. Data demonstrated that macropinocytosis is employed by most cell lines, while clathrin-dependent pathways serve as secondary uptake pathways in some cell lines⁸⁹. Ongoing work is focusing on modifying the structure of LOX-PP to enhance its uptake by cancer cells and increase its effectiveness, and to establish which targets are the most important in mediating the tumor inhibitor properties of LOX-PP.

2.1.2. Lysyl oxidase like-1 (LOXL1)—LOXL1 has been linked primarily to elastin maturation. LOXL1 null mice experience skin, uterine, and lung abnormalities and females exhibit uterine prolapse¹¹⁵⁻¹¹⁷. LOXL1 has been shown to be closely associated with elastic fibers in vivo¹¹⁸. However, a recent report identifies a bone abnormality in *LOXL1* null mice which occurs only in females. Mutant mice have a deficiency in trabecular bone in both long bones and vertebrae¹¹⁹. Immunohistochemistry demonstrated strong expression of LOXL1 in growth plate chondrocytes, suggesting that LOXL1 is important not only for elastin maturation, but also possibly for type II collagen. Moreover, data implicate sex hormone regulation of LOXL1 may be an important aspect of its biological control.

A variety of polymorphisms in LOXL1 have been genetically linked to ocular exfoliation syndrome and glaucoma which may be caused by aberrant regulation of expression of LOXL1 and/or missense mutations combined with environmental stressors^{118, 120-123}. LOXL1 null mice do not exhibit glaucoma, but do exhibit intracellular subcapsular vesicles¹¹⁸. Intracellular vesicle accumulations in subcapsular cells precedes development of cataracts in some animal models of cataract development¹²⁴. Abnormalities in LOXL1 expression or structure seem likely to contribute to some ocular abnormalities, but may not be primary determinants.

Only a few papers and conflicting data exist regarding roles for LOXL1 in cancer biology. One report indicates that LOXL1 and LOXL4 expression are anti-tumorigenic and inhibit RAS and ERK1/2 signaling in bladder cancer¹²⁵, while LOXL1 was suggested to enhance lung metastasis in low pH hypoxic tumor microenvironments¹²⁶. A role for caffeine-stimulated LOXL1 expression in inhibiting tumor metastasis has also been suggested¹²⁷. Additional studies seem to be required to better understand these findings.

2.1.3. Lysyl oxidase-like 2—There is a great deal of interest in LOXL2, particularly in cancer biology. It is widely over-expressed in cancers, including metastatic cancers. For example, high levels of LOXL2 occur in colon cancer associated fibroblasts¹²⁸, skin cancer¹²⁹, oral cancer¹³⁰, skin and head and neck squamous cell carcinoma¹⁰¹, liver metastasis¹⁰³, cholangiocarcinoma¹³¹, breast cancer^{76, 92, 132, 133}, and gastric cancer metastasis¹⁰². Attenuation of LOXL2 expression was shown to inhibit metastasis or the invasive cell phenotypes in most of these studies. One study documented LOXL2 down regulation in non-small cell lung cancers¹³⁴.

A variety of mechanisms for LOXL2 promotion of metastasis are being investigated and a rather complex picture has emerged. MicroRNA down-regulation of LOXL2 has recently

been shown to be diminished in head and neck, renal and lung cancers^{97, 135, 136} suggesting that regulatory pathways which control expression of LOXL2 may be significant drivers of metastasis. Evidence for both tumor secreted and stromal cell secreted LOXL2 in promoting metastasis has been found which may contribute to matrix stiffness, FAK activation and integrin signaling and control of cancer cell migration^{94, 128}. LOXL2 expression in cancer cells is stimulated under hypoxic conditions, and evidence for HIF-1 transcriptional regulation of LOXL2 has been presented¹³⁷. Extracellular interaction of LOXL2 with HSP90 to stimulate migration and metastasis has recently been highlighted¹³⁸. Several papers investigate roles and mechanisms of intracellular LOXL2 in promoting cancer metastasis. Direct nuclear interactions of LOXL2 with Snail and down-regulation of E-cadherin to stimulate epithelial to mesenchymal transition and migration of cancer cells has been reported, but no evidence for LOXL2 oxidation of Snail has so far been reported¹³⁹. Interestingly, enzymatically inactive forms of LOXL2 were also able to interact with Snail and down-regulate E-cadherin^{133, 140}. Moreover, expression of full length LOXL2 or of an enzymatically inactive truncated form of LOXL2 were both found to down-regulate the promoter activity of claudin 1 and *Lgl2* promoters independent of Snail in MDA-MB-231 breast cancer cells. Claudin 1 and *Lgl2*, like E-cadherin are epithelial cell adhesion proteins critical for normal epithelial polarity¹⁰⁰. LOXL2 in which essential copper-binding histidine residues were mutated to glutamine, thus eliminating enzyme activity, still bound to Snail and down-regulated E-cadherin expression¹⁴⁰. Similarly, binding to the *E-cadherin* and *claudin 1* promoters remained unaffected by these mutations in MDA-MB-231 human breast cancer cells and in MDCK cells, an epithelial cell line. Finally, FAK activation and cell migration in these cell lines was equally stimulated by active and inactive forms of LOXL2. The authors conclude that stimulation of epithelial to mesenchymal transition (EMT) mediated by intracellular LOXL2 occurs independent of its enzyme activity¹⁴⁰. As noted, however, LOXL2, like all other isoforms, is a secreted protein, and intracellular trafficking that leads to nuclear localization of LOXL2 and details regarding its interactions with transcription factors remain to be determined, and are of importance regarding under what conditions LOXL2 modulation of EMT is regulated. Reports of splice variants, and intracellular protein proteolytic processing are of interest and may be related to these questions of intracellular trafficking^{99, 141}.

Several reports suggest that LOXL2 can directly oxidize tri-methylated lysine residues in histones and TAFIIID, another nuclear protein, and thereby promote an invasive phenotype¹⁴²⁻¹⁴⁵. Although there is no doubt that excess LOXL2 expression can promote EMT and an invasive phenotype, the notion of direct oxidation of nuclear trimethyl lysine residues by LOXL2 in our opinion requires further investigation. As noted above, secondary and tertiary amines do not serve as substrates of LOX³⁰. The LTQ cofactor cannot form a Schiff base with tertiary amines; and the LTQ cofactor which functions in LOX is presumed to function in all other lysyl oxidase isoforms due to sequence conservation and the fact that they all oxidize primary amines. Thus, basic biochemical questions remain regarding the mechanism of action of LOXL2 and its apparent ability to oxidize tri-methylated lysine residues. In light of the proposed mechanism for tri-methyl lysine oxidation by LOXL2¹⁴⁵, one approach might be to directly assess the substrate potential of a variety of primary,

secondary and tertiary amines and corresponding primary alcohols for aldehyde generation by purified LOXL2.

LOXL2 is upregulated under hypoxic conditions and has been shown to participate in normal angiogenesis which was dependent on both non-enzymatic and enzymatic activities. Initial organization of endothelial cells into tubes was dependent on LOXL2 expression but not enzyme activity, while stabilization of the basement membrane structures and stabilization of vessels required active LOXL2¹⁴⁶. Tumor growth requires a blood supply and LOXL2 has been shown to participate in tumor angiogenesis¹⁴⁷.

In formation of mineralized tissues, LOX is the predominant isoform elaborated by osteoblasts^{35, 148}. Interestingly, LOXL2 appears to have negative consequences for mineralization by osteoblasts and odontoblasts. In odontoblast differentiation, LOXL2 expression was lower than all other isoforms¹⁴⁹, while in BMP-2-stimulated osteoblast differentiation, LOXL2 addition resulted in highly cross-linked collagen and poor mineralization¹⁵⁰. However, LOXL2 is critically required for chondrocyte differentiation. Knock-down of LOXL2 profoundly inhibits development of chondrocytes in vitro, and expression of LOXL2 in healing long bones correlates positively with the chondrogenic phase in vivo⁴.

LOXL2 null and overexpressing mice have recently been generated¹²⁹. LOXL2 deletion was accomplished by deletion of exon 2 and resulted in perinatal lethality in 50% of the mice. Heart defects characterized by disrupted ventricular septa were noted in 40% of the surviving homozygous null mice. Homozygous mice overexpressing LOXL2 were almost all sterile with poor testicle formation and low sperm production. Fibrosis in the epididymis and inflammation was observed histologically, accompanied by low expression of E-cadherin and claudin of basal epithelial cells of the epididymis, consistent with the EMT activity of LOXL2 previously identified^{100, 139, 140}. LOXL2 null and over-expressing mice were subjected to a chemically-induced model of squamous cell carcinoma¹²⁹. Interestingly, LOXL2 over-expressing mice developed cancer earlier and with greater severity than the LOXL2 null mice. Lesions in LOXL2 null mice were smaller than the corresponding wildtype littermates. LOXL2 was observed to inhibit epidermal cell differentiation mediated by its inhibition of the Notch1 pathway apparently mediated by LOXL2 binding to the Notch1 promoter, implicating a mechanism of action of LOXL2 which occurs in the nucleus of cells without oxidation of trimethylated histone H3K4¹²⁹.

2.1.4. Lysyl oxidase-like 3 (LOXL3)—LOXL3 null mice have recently been characterized and are perinatal lethal, exhibit cleft palate and vertebral defects. Collagen density was abnormally low in both the palate and vertebral primordia in knockout embryos. Both cleft palate and ocular abnormalities occur in a human family which has missense mutation in the *Loxl3* gene, but the ocular phenotype was not observed in mice^{151, 152}. Two splice variants of LOXL3 have been identified^{153, 154}. One variant is initiated from an alternative promoter and has been shown to have catalytic activity and distinct tissue-specific expression patterns compared to full-length LOXL3¹⁵⁴. The biological relevance of these findings remain to be determined. As noted, LOXL3 is often up-regulated in concert with the

other four isoforms in fibrosis, but no specific therapeutic opportunities for LOXL3 have become apparent so far to our knowledge.

2.1.5. Lysyl oxidase-like 4 (LOXL4)—LOXL4 is expressed in vascular tissues and has normal functions in connective tissue remodeling. Excess LOXL4, like LOX, has been linked to vascular fibrotic pathologies¹⁵⁵. Splice variants of LOXL4 have been identified, and it has been proposed that shorter isoforms could stimulate metastasis while full length LOXL4 may have tumor inhibitory properties^{156, 157}. LOXL4 expression appears to be a reliable marker for head and neck cancer development¹⁵⁸⁻¹⁶⁰. LOXL4 is overexpressed in gastric cancer and contributes to FAK activation and integrin signaling¹⁰⁴.

3. Therapeutic opportunities

Lysyl oxidase enzyme activity has long been considered to be a viable target to treat fibrosis³⁹. BAPN is a highly effective and specific inhibitor of all lysyl oxidases in vitro, but has the disadvantage that it is oxidized by other amine oxidases that can lead to the production of toxic products^{161, 162}. The copper chelator tetrathiomolybdate is an effective lysyl oxidase activity inhibitor as well¹⁶³⁻¹⁶⁵, but it has the potential to cause significant toxicity or side effects due to the importance of copper in mitochondrial respiration and energy production to normal physiology¹⁶⁶. Interestingly, novel LOX active site-directed inhibitor development is underway, some of which are selective for specific lysyl oxidase isoforms¹⁶⁷. These inhibitors have enormous potential for treating LOXL2 driven metastatic cancers which have been summarized above. Preliminary data indicate that LOXL2 inhibitors can effectively inhibit bleomycin-induced lung fibrosis without toxicity¹⁶⁸. Clearly much work needs to be done before human trials are undertaken, but there is now reason to be optimistic that the development of effective small molecule lysyl oxidase inhibitors to address fibrosis and cancer can be accomplished.

Therapeutic antibodies targeting LOX and LOXL2 have been described and employed in preclinical studies^{40, 94, 169}, and some human clinical trials have apparently been initiated by at least one pharmaceutical company. One limitation to these reagents may be that the negative effects of some LOX isoforms have been reported to be mediated not in the extracellular environment, but by intracellular targets which may not be accessible to antibody-based reagents.

LOX-PP has tumor growth inhibitor properties, is a natural product expressed by mammalian cells, and can enter cells from the extracellular environment. LOX-PP has a variety of molecular targets all of which appear to promote cancer development or metastasis, except possibly when injected into bones¹⁷⁰. Thus, LOX-PP may have an advantage over reagents that are designed to target only one molecule, due to the plasticity of cancer and the seemingly inevitable development of resistance to chemotherapeutics. A slow release formulation has been shown to be effective at inhibiting the growth of a pre-existing breast cancer xenograft, suggesting that formulations of LOX-PP or a derivative to extend its half-life so that it is effective in vivo are possible⁸⁸.

4. Conclusion

At least three therapeutic approaches, therefore, exist based on what is known so far regarding the biology of the lysyl oxidases: novel small molecule inhibitors, therapeutic antibodies, and molecules and formulations based on LOX-PP structure and activity. Additional opportunities seem likely to be developed after the biological functions and binding partners of the propeptide regions of LOXL1 and LOXL2 – LOXL4 and splice variants have been determined, and the novel substrates of all five active lysyl oxidase enzymes implied in many recent studies are actually identified.

5. Expert Opinion

Key findings are that lysyl oxidase enzyme activity from all 5 isoforms drives both fibrosis and cancer metastasis. Very significant progress in developing small molecule pan-lysyl oxidase isoform inhibitors and isoform-specific lysyl oxidase inhibitors is a promising current avenue of ongoing research that seems likely to lead to new therapies for fibrosis and possibly metastatic cancer ^{167, 168}. Therapeutic antibodies that block the enzyme activity of lysyl oxidase isoforms have been developed in pre-clinical studies ¹⁷¹. LOXL2 has emerged as an isoform that is of particular importance in the development of cancer and metastasis. LOX-PP derived from pro-LOX, however, is a tumor growth inhibitor and tumor suppressor ^{6, 91}. As a natural product, an increased understanding of its mechanisms of action and intracellular trafficking and identification of its most important targets will inform the degree to which a LOX-PP-derived therapeutic can be developed, possibly with little or no associated toxicity.

Although the evidence for the existence of novel substrates of lysyl oxidases that lead to some of these enzymes' pathologic effects is convincing, identification of these substrates and which lysine residue(s) are oxidized is lacking. This structural information is critically important for the development of, for example, strategies to block substrate activity perhaps with substrate-specific therapeutic antibodies that would prevent access by lysyl oxidases. It is also important to pay close attention to the structure of each lysyl oxidase isoform and to the enzymology of this family. The biosynthetic pathway of LOXL2 – LOXL4 is unclear at this time with respect to whether or not biosynthetic proteolytic processing occurs, and whether this is needed for enzyme activation. The origins and fates of intracellular lysyl oxidases are largely unknown regarding how these secreted proteins become intracellular, and how they traffic through the cell, sometimes localizing in the nucleus. No substrate specificity studies or classical enzymology has been reported on any isoform except LOX, and only one paper has been published along these lines on LOXL2 ¹⁴. Confirmation of copper and LTQ cofactor content is important to establish in all isoforms. There is a great need to crystalize lysyl oxidase isoforms to gain detailed structural information, and recombinant expression of active lysyl oxidase isoforms has been very challenging. Lysyl oxidases from some commercial sources are inactive. LOXL2 from R&DSys, however, is clearly an active enzyme and is an important contribution to the field.

Acknowledgments

The author was supported by the National Institutes of Health under grant number R21DE023973 from the National Institute of Dental and Craniofacial Research (NIDCR). P Trackman also serves as a consultant for Pharmaxis Corp., Sydney, Australia.

Reference annotations

* Of interest

** Of considerable interest

1. Kagan HM, Trackman PC. Properties and function of lysyl oxidase. *American journal of respiratory cell and molecular biology*. 1991 Sep; 5(3):206–10. [PubMed: 1680355]
2. Le Provost GS, Debret R, Cenizo V, Aimond G, Pez F, Kaniewski B, et al. Lysyl oxidase silencing impairs keratinocyte differentiation in a reconstructed-epidermis model. *Experimental dermatology*. 2010 Dec; 19(12):1080–7. [PubMed: 20812961]
3. Lugassy J, Zaffryar-Eilot S, Soueid S, Mordoviz A, Smith V, Kessler O, et al. The enzymatic activity of lysyl oxidase-like-2 (LOXL2) is not required for LOXL2-induced inhibition of keratinocyte differentiation. *The Journal of biological chemistry*. 2012 Jan 27; 287(5):3541–9. [PubMed: 22157764]
4. Iftikhar M, Hurtado P, Bais MV, Wigner N, Stephens DN, Gerstenfeld LC, et al. Lysyl oxidase-like-2 (LOXL2) is a major isoform in chondrocytes and is critically required for differentiation. *The Journal of biological chemistry*. 2011 Jan 14; 286(2):909–18. [PubMed: 21071451]
5. Min C, Kirsch KH, Zhao Y, Jeay S, Palamakumbura AH, Trackman PC, et al. The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of Her-2/neu-driven breast cancer. *Cancer research*. 2007 Feb 1; 67(3):1105–12. [PubMed: 17283144]
- **6. Palamakumbura AH, Jeay S, Guo Y, Pischon N, Sommer P, Sonenshein GE, et al. The propeptide domain of lysyl oxidase induces phenotypic reversion of ras-transformed cells. *The Journal of biological chemistry*. 2004 Sep 24; 279(39):40593–600. This paper demonstrated that the tumor inhibitor properties of lysyl oxidase is mediated by the propeptide domain and not the active enzyme, as previously assumed. [PubMed: 15277520]
- *7. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. *Nature*. 2006 Apr 27; 440(7088):1222–6. This is a highly cited paper connecting lysyl oxidase expression and activity with metastasis. [PubMed: 16642001]
- *8. Khosravi R, Sodek KL, Xu WP, Bais MV, Saxena D, Faibish M, et al. A novel function for lysyl oxidase in pluripotent mesenchymal cell proliferation and relevance to inflammation-associated osteopenia. *PloS one*. 2014; 9(6):e100669. This paper demonstrates that lysyl oxidase expression and enzyme activity promotes proliferation of pluripotent cells and is required for ultimate differentiation into osteoblasts. [PubMed: 24971753]
9. Payne SL, Fogelgren B, Hess AR, Seftor EA, Wiley EL, Fong SF, et al. Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. *Cancer research*. 2005 Dec 15; 65(24):11429–36. [PubMed: 16357151]
- *10. Bignon M, Pichol-Thievend C, Hardouin J, Malbouyres M, Brechot N, Nasciutti L, et al. Lysyl oxidase-like protein-2 regulates sprouting angiogenesis and type IV collagen assembly in the endothelial basement membrane. *Blood*. 2011 Oct 6; 118(14):3979–89. Data show that LOXL2 promotes angiogenesis independent of its enzyme activity, while also requiring enzyme activity for final stabilization of capillaries. [PubMed: 21835952]
11. Kagan HM, Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. *Journal of cellular biochemistry*. 2003 Mar 1; 88(4):660–72. [PubMed: 12577300]
12. Panchenko MV, Stetler-Stevenson WG, Trubetskoy OV, Gacheru SN, Kagan HM. Metalloproteinase activity secreted by fibrogenic cells in the processing of prolysyl oxidase. Potential role of procollagen C-proteinase. *The Journal of biological chemistry*. 1996 Mar 22; 271(12):7113–9. [PubMed: 8636146]

- *13. Uzel MI, Scott IC, Babakhanlou-Chase H, Palamakumbura AH, Pappano WN, Hong HH, et al. Multiple bone morphogenetic protein 1-related mammalian metalloproteinases process pro-lysyl oxidase at the correct physiological site and control lysyl oxidase activation in mouse embryo fibroblast cultures. *The Journal of biological chemistry*. 2001 Jun 22; 276(25):22537–43. Procollagen C-proteinases were shown to be responsible for extracellular proteolytic processing of prolysyl oxidase to form active lysyl oxidase and release the lysyl oxidase propeptide. [PubMed: 11313359]
- *14. Rodriguez HM, Vaysberg M, Mikels A, McCauley S, Velayo AC, Garcia C, et al. Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor. *The Journal of biological chemistry*. 2010 Jul 2; 285(27):20964–74. Definitive proof that LOXL2 encodes an active enzyme was presented. [PubMed: 20439985]
15. Csiszar K. Lysyl oxidases: a novel multifunctional amine oxidase family. *Progress in nucleic acid research and molecular biology*. 2001; 70:1–32. [PubMed: 11642359]
16. Mäki JM, Tikkanen H, Kivirikko KI. Cloning and characterization of a fifth human lysyl oxidase isoenzyme: the third member of the lysyl oxidase-related subfamily with four scavenger receptor cysteine-rich domains. *Matrix Biology*. 2001 Nov; 20(7):493–96. [PubMed: 11691589]
- *17. Thomassin L, Werneck CC, Broekelmann TJ, Gleyzal C, Hornstra IK, Mecham RP, et al. The Pro-regions of lysyl oxidase and lysyl oxidase-like 1 are required for deposition onto elastic fibers. *The Journal of biological chemistry*. 2005 Dec 30; 280(52):42848–55. Functionality of proregions of LOX and LOXL1 was demonstrated. [PubMed: 16251195]
- *18. Tchapanian EH, Uriu-Adams JY, Keen CL, Mitchell AE, Rucker RB. Lysyl oxidase and P-ATPase-7A expression during embryonic development in the rat. *Archives of biochemistry and biophysics*. 2000 Jul 1; 379(1):71–7. This study provides insights into copper transport into lysyl oxidase. [PubMed: 10864443]
- **19. Lopez KM, Greenaway FT. Identification of the copper-binding ligands of lysyl oxidase. *Journal of neural transmission (Vienna, Austria : 1996)*. 2011 Jul; 118(7):1101–9. Copper-binding amino acids in LOX were experimentally determined.
20. Krebs CJ, Krawetz SA. Lysyl oxidase copper-talon complex: a model. *Biochimica et biophysica acta*. 1993 Sep 3; 1202(1):7–12. [PubMed: 8104038]
21. Gacheru SN, Trackman PC, Shah MA, O'Gara CY, Spacciapoli P, Greenaway FT, et al. Structural and catalytic properties of copper in lysyl oxidase. *The Journal of biological chemistry*. 1990 Nov 5; 265(31):19022–7. [PubMed: 1977746]
22. Tang C, Klinman JP. The catalytic function of bovine lysyl oxidase in the absence of copper. *The Journal of biological chemistry*. 2001 Aug 17; 276(33):30575–8. [PubMed: 11395477]
- **23. Wang SX, Mure M, Medzihradsky KF, Burlingame AL, Brown DE, Dooley DM, et al. A crosslinked cofactor in lysyl oxidase: redox function for amino acid side chains. *Science*. 1996 Aug 23; 273(5278):1078–84. Definitive evidence for LTQ as the elusive carbonyl cofactor in LOX was provided. [PubMed: 8688089]
24. Wang SX, Nakamura N, Mure M, Klinman JP, Sanders-Loehr J. Characterization of the native lysine tyrosylquinone cofactor in lysyl oxidase by Raman spectroscopy. *The Journal of biological chemistry*. 1997 Nov 14; 272(46):28841–4. [PubMed: 9360949]
25. Bollinger JA, Brown DE, Dooley DM. The Formation of lysine tyrosylquinone (LTQ) is a self-processing reaction. Expression and characterization of a Drosophila lysyl oxidase. *Biochemistry*. 2005 Sep 6; 44(35):11708–14. [PubMed: 16128571]
26. Dubois JL, Klinman JP. Mechanism of post-translational quinone formation in copper amine oxidases and its relationship to the catalytic turnover. *Archives of biochemistry and biophysics*. 2005 Jan 1; 433(1):255–65. [PubMed: 15581581]
27. Mohankumar A, Renganathan B, Karunakaran C, Chidambaram S, Konerirajapuram Natarajan S. Peptides derived from the copper-binding region of lysyl oxidase exhibit antiangiogenic properties by inhibiting enzyme activity: an in vitro study. *Journal of peptide science : an official publication of the European Peptide Society*. 2014 Nov; 20(11):837–49. [PubMed: 25044713]
- **28. Trackman PC, Pratt AM, Wolanski A, Tang SS, Offner GD, Troxler RF, et al. Cloning of rat aorta lysyl oxidase cDNA: complete codons and predicted amino acid sequence. *Biochemistry*. 1990 May 22; 29(20):4863–70. [PubMed: 1973052]

- **29. Trackman PC, Pratt AM, Wolanski A, Tang SS, Offner GD, Troxler RF, et al. Cloning of rat aorta lysyl oxidase cDNA: complete codons and predicted amino acid sequence. *Biochemistry*. 1991 Aug 20;30(33):8282. These reports constitute the first reports of molecular cloning of any form of mamalian lysyl oxidase. [PubMed: 1678281]
30. Lucero HA, Kagan HM. Lysyl oxidase: an oxidative enzyme and effector of cell function. *Cellular and molecular life sciences : CMLS*. 2006 Oct; 63(19-20):2304–16. [PubMed: 16909208]
31. Williamson PR, Kagan HM. Reaction pathway of bovine aortic lysyl oxidase. *The Journal of biological chemistry*. 1986 Jul 15; 261(20):9477–82. [PubMed: 2873143]
32. Kataoka M, Oya H, Tominaga A, Otsu M, Okajima T, Tanizawa K, et al. Detection of the reaction intermediates catalyzed by a copper amine oxidase. *Journal of synchrotron radiation*. 2011 Jan; 18(1):58–61. [PubMed: 21169693]
33. Taki M, Murakawa T, Nakamoto T, Uchida M, Hayashi H, Tanizawa K, et al. Further insight into the mechanism of stereoselective proton abstraction by bacterial copper amine oxidase. *Biochemistry*. 2008 Jul 22; 47(29):7726–33. [PubMed: 18627131]
- **34. Trackman PC, Kagan HM. Nonpeptidyl amine inhibitors are substrates of lysyl oxidase. *The Journal of biological chemistry*. 1979 Aug 25; 254(16):7831–6. This paper provided evidence that LOX can oxidize low molecular weight amine compounds, rather than only collagens and elastin, leading to the later development of enzyme-coupled assays and kinetic characterization of the LOX catalytic mechanism. [PubMed: 38246]
- **35. Trackman PC, Bedell-Hogan D, Tang J, Kagan HM. Post-translational glycosylation and proteolytic processing of a lysyl oxidase precursor. *The Journal of biological chemistry*. 1992 Apr 25; 267(12):8666–71. Basic features of the biosynthetic pathway of lysyl oxidase were identified. [PubMed: 1349020]
36. Du J, Hincke MT, Rose-Martel M, Hennequet-Antier C, Brionne A, Cogburn LA, et al. Identifying specific proteins involved in eggshell membrane formation using gene expression analysis and bioinformatics. *BMC genomics*. 2015; 16(1):792. [PubMed: 26470705]
37. Sharma-Bhandari A, Park SH, Kim JY, Oh J, Kim Y. Lysyl oxidase modulates the osteoblast differentiation of primary mouse calvaria cells. *International journal of molecular medicine*. 2015 Dec; 36(6):1664–70. [PubMed: 26497171]
38. Atsawasuwan P, Mochida Y, Parisuthiman D, Yamauchi M. Expression of lysyl oxidase isoforms in MC3T3-E1 osteoblastic cells. *Biochemical and biophysical research communications*. 2005 Feb 25; 327(4):1042–6. [PubMed: 15652501]
- **39. Maki JM, Rasanen J, Tikkanen H, Sormunen R, Makikallio K, Kivirikko KI, et al. Inactivation of the lysyl oxidase gene *Lox* leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice. *Circulation*. 2002 Nov 5; 106(19):2503–9. The phenotype of the LOX knockout mouse is provided. [PubMed: 12417550]
- **40. Hornstra IK, Birge S, Starcher B, Bailey AJ, Mecham RP, Shapiro SD. Lysyl oxidase is required for vascular and diaphragmatic development in mice. *The Journal of biological chemistry*. 2003 Apr 18; 278(16):14387–93. The phenotype of the LOX knockout mouse is provided. [PubMed: 12473682]
41. Kagan HM. Intra- and extracellular enzymes of collagen biosynthesis as biological and chemical targets in the control of fibrosis. *Acta tropica*. 2000 Oct 23; 77(1):147–52. [PubMed: 10996130]
42. Gonzalez-Santamaria J, Villalba M, Busnadiego O, Lopez-Olaneta MM, Sandoval P, Snabel J, et al. Matrix cross-linking lysyl oxidases are induced in response to myocardial infarction and promote cardiac dysfunction. *Cardiovascular research*. 2016 Jan 1; 109(1):67–78. [PubMed: 26260798]
43. Iwasaki A, Sakai K, Moriya K, Sasaki T, Keene DR, Akhtar R, et al. Molecular mechanism responsible for fibronectin-controlled alterations in tissue stiffness in advanced chronic liver fibrogenesis. *The Journal of biological chemistry*. 2016 Jan 1; 291(1):72–88. [PubMed: 26553870]
44. Lytle KA, Depner CM, Wong CP, Jump DB. Docosahexaenoic acid attenuates Western diet-induced hepatic fibrosis in *Ldlr*^{-/-} mice by targeting the TGFbeta-Smad3 pathway. *Journal of lipid research*. 2015 Oct; 56(10):1936–46. [PubMed: 26315048]

45. Mesarwi OA, Shin MK, Drager LF, Bevans-Fonti S, Jun JC, Putcha N, et al. Lysyl Oxidase as a Serum Biomarker of Liver Fibrosis in Patients with Severe Obesity and Obstructive Sleep Apnea. *Sleep*. 2015; 38(10):1583–91. [PubMed: 26085300]
46. Ruiz LA, Baez-Vega PM, Ruiz A, Peterse DP, Monteiro JB, Bracero N, et al. Dysregulation of Lysyl Oxidase Expression in Lesions and Endometrium of Women With Endometriosis. *Reproductive sciences (Thousand Oaks, Calif)*. 2015 Dec; 22(12):1496–508.
47. Rosin NL, Sopel MJ, Falkenham A, Lee TD, Legare JF. Disruption of collagen homeostasis can reverse established age-related myocardial fibrosis. *The American journal of pathology*. 2015 Mar; 185(3):631–42. [PubMed: 25701883]
48. Cheng T, Liu Q, Zhang R, Zhang Y, Chen J, Yu R, et al. Lysyl oxidase promotes bleomycin-induced lung fibrosis through modulating inflammation. *Journal of molecular cell biology*. 2014 Dec; 6(6):506–15. [PubMed: 25348956]
49. Nave AH, Mizikova I, Niess G, Steenbock H, Reichenberger F, Talavera ML, et al. Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension. *Arterioscler Thromb Vasc Biol*. 2014 Jul; 34(7):1446–58. [PubMed: 24833797]
50. Lopez B, Gonzalez A, Lindner D, Westermann D, Ravassa S, Beaumont J, et al. Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase? *Cardiovascular research*. 2013 Jul 1; 99(1):111–20. [PubMed: 23619422]
51. Almassian B, Trackman PC, Iguchi H, Boak A, Calvaresi D, Kagan HM. Induction of lung lysyl oxidase activity and lysyl oxidase protein by exposure of rats to cadmium chloride: properties of the induced enzyme. *Connective tissue research*. 1991; 25(3-4):197–208. [PubMed: 1676359]
52. Blaauboer ME, Emson CL, Verschuren L, van Erk M, Turner SM, Everts V, et al. Novel combination of collagen dynamics analysis and transcriptional profiling reveals fibrosis-relevant genes and pathways. *Matrix biology : journal of the International Society for Matrix Biology*. 2013 Oct-Nov; 32(7-8):424–31. [PubMed: 23648810]
53. Wang J, Zhu Y, Tan J, Meng X, Xie H, Wang R. Lysyl oxidase promotes epithelial-to-mesenchymal transition during paraquat-induced pulmonary fibrosis. *Molecular bioSystems*. 2016 Jan 26; 12(2):499–507. [PubMed: 26670953]
54. Kenyon NJ, Ward RW, McGrew G, Last JA. TGF-beta1 causes airway fibrosis and increased collagen I and III mRNA in mice. *Thorax*. 2003 Sep; 58(9):772–7. [PubMed: 12947136]
55. Chung EJ, Hudak K, Horton JA, White A, Scroggins BT, Vaswani S, et al. Transforming growth factor alpha is a critical mediator of radiation lung injury. *Radiation research*. 2014 Sep; 182(3):350–62. [PubMed: 25117621]
56. Liu, SB.; Ikenaga, N.; Peng, ZW.; Sverdlov, DY.; Greenstein, A.; Smith, V., et al. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2015 Dec 23. Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice. *fj*.14-268425
57. Ricard-Blum S, Bresson-Hadni S, Guerret S, Grenard P, Volle PJ, Risteli L, et al. Mechanism of collagen network stabilization in human irreversible granulomatous liver fibrosis. *Gastroenterology*. 1996 Jul; 111(1):172–82. [PubMed: 8698196]
58. McPhie JL. The activity of lysyl oxidase in experimental hepatic fibrosis. *Hepato-gastroenterology*. 1981 Oct; 28(5):240–1. [PubMed: 6124494]
59. Adam O, Zimmer C, Hanke N, Hartmann RW, Klemmer B, Bohm M, et al. Inhibition of aldosterone synthase (CYP11B2) by torasemide prevents atrial fibrosis and atrial fibrillation in mice. *Journal of molecular and cellular cardiology*. 2015 Aug; 85:140–50. [PubMed: 26047574]
60. Gonzalez GE, Rhaleb NE, Nakagawa P, Liao TD, Liu Y, Leung P, et al. N-acetyl-seryl-aspartyl-lysyl-proline reduces cardiac collagen cross-linking and inflammation in angiotensin II-induced hypertensive rats. *Clin Sci (Lond)*. 2014 Jan 1; 126(1):85–94. [PubMed: 23834332]
61. Rimar D, Rosner I, Nov Y, Slobodin G, Rozenbaum M, Halasz K, et al. Brief report: lysyl oxidase is a potential biomarker of fibrosis in systemic sclerosis. *Arthritis & rheumatology (Hoboken, NJ)*. 2014 Mar; 66(3):726–30.
62. Mittapalli VR, Madl J, Loffek S, Kiritsi D, Kern JS, Romer W, et al. Injury-driven Stiffening of the Dermis Expedites Skin Carcinoma Progression. *Cancer research*. 2015 Dec 16. Epub ahead of print.

63. Chanoki M, Ishii M, Kobayashi H, Fushida H, Yashiro N, Hamada T, et al. Increased expression of lysyl oxidase in skin with scleroderma. *The British journal of dermatology*. 1995 Nov; 133(5): 710–5. [PubMed: 8555021]
64. Hong HH, Uzel MI, Duan C, Sheff MC, Trackman PC. Regulation of lysyl oxidase, collagen, and connective tissue growth factor by TGF-beta1 and detection in human gingiva. *Lab Invest*. 1999 Dec; 79(12):1655–67. [PubMed: 10616214]
65. Assaggaf MA, Kantarci A, Sume SS, Trackman PC. Prevention of phenytoin-induced gingival overgrowth by lovastatin in mice. *The American journal of pathology*. 2015 Jun; 185(6):1588–99. [PubMed: 25843680]
- **66. Eliades A, Papadantonakis N, Bhupatiraju A, Burrige KA, Johnston-Cox HA, Migliaccio AR, et al. Control of megakaryocyte expansion and bone marrow fibrosis by lysyl oxidase. *The Journal of biological chemistry*. 2011 Aug 5; 286(31):27630–8. Evidence for active lysyl oxidase in enhancing PDGF signaling and proliferation of megakaryocytes was presented, while excess LOX in a model of myeloproliferative disease promoted myelofibrosis. [PubMed: 21665949]
67. Tadmor T, Bejar J, Attias D, Mischenko E, Sabo E, Neufeld G, et al. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms. *American journal of hematology*. 2013 May; 88(5):355–8. [PubMed: 23494965]
68. Eliades A, Papadantonakis N, Matsuura S, Mi R, Bais MV, Trackman P, et al. Megakaryocyte polyploidy is inhibited by lysyl oxidase propeptide. *Cell Cycle*. 2013 Apr 15; 12(8):1242–50. [PubMed: 23518500]
69. Behl Y, Krothapalli P, Desta T, DiPiazza A, Roy S, Graves DT. Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. *The American journal of pathology*. 2008 May; 172(5): 1411–8. [PubMed: 18403591]
70. Chronopoulos A, Trudeau K, Roy S, Huang H, Viores SA, Roy S. High glucose-induced altered basement membrane composition and structure increases trans-endothelial permeability: implications for diabetic retinopathy. *Current eye research*. 2011 Aug; 36(8):747–53. [PubMed: 21780924]
71. Roy S, Ha J, Trudeau K, Beglova E. Vascular basement membrane thickening in diabetic retinopathy. *Current eye research*. 2010 Dec; 35(12):1045–56. [PubMed: 20929292]
72. Chronopoulos A, Tang A, Beglova E, Trackman PC, Roy S. High glucose increases lysyl oxidase expression and activity in retinal endothelial cells: mechanism for compromised extracellular matrix barrier function. *Diabetes*. 2010 Dec; 59(12):3159–66. [PubMed: 20823103]
73. Van Bergen T, Spangler R, Marshall D, Hollanders K, Van de Veire S, Vandewalle E, et al. The Role of LOX and LOXL2 in the Pathogenesis of an Experimental Model of Choroidal Neovascularization. *Investigative ophthalmology & visual science*. 2015 Aug; 56(9):5280–9. [PubMed: 26258612]
74. Baker AM, Cox TR, Bird D, Lang G, Murray GI, Sun XF, et al. The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer. *Journal of the National Cancer Institute*. 2011 Mar 2; 103(5):407–24. [PubMed: 21282564]
75. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. *Cell*. 2009 Nov 25; 139(5):891–906. [PubMed: 19931152]
76. Le QT, Harris J, Magliocco AM, Kong CS, Diaz R, Shin B, et al. Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2009 Sep 10; 27(26):4281–6. [PubMed: 19667273]
77. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. *Cancer cell*. 2009 Jan 6; 15(1):35–44. [PubMed: 19111879]
78. Kirschmann DA, Seftor EA, Fong SF, Nieva DR, Sullivan CM, Edwards EM, et al. A molecular role for lysyl oxidase in breast cancer invasion. *Cancer research*. 2002 Aug 1; 62(15):4478–83. [PubMed: 12154058]

- *79. Kirschmann DA, Seftor EA, Nieva DR, Mariano EA, Hendrix MJ. Differentially expressed genes associated with the metastatic phenotype in breast cancer. *Breast cancer research and treatment*. 1999 May; 55(2):127–36. This is possibly the first report which established a correlation between metastasis and increased lysyl oxidase expression. [PubMed: 10481940]
- *80. Payne SL, Hendrix MJ, Kirschmann DA. Lysyl oxidase regulates actin filament formation through the p130(Cas)/Crk/DOCK180 signaling complex. *Journal of cellular biochemistry*. 2006 Jul 1; 98(4):827–37. The paper introduced the ideas that LOX influences integrin signaling and cell adhesion. [PubMed: 16440329]
81. Cox TR, Bird D, Baker AM, Barker HE, Ho MW, Lang G, et al. LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. *Cancer research*. 2013 Mar 15; 73(6):1721–32. [PubMed: 23345161]
82. Baker AM, Bird D, Welte JC, Gourlaouen M, Lang G, Murray GI, et al. Lysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesis. *Cancer research*. 2013 Jan 15; 73(2):583–94. [PubMed: 23188504]
83. Cox TR, Rumney RM, Schoof EM, Perryman L, Hoyer AM, Agrawal A, et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. *Nature*. 2015 Jun 4; 522(7554):106–10. [PubMed: 26017313]
84. Baker AM, Bird D, Lang G, Cox TR, Erler JT. Lysyl oxidase enzymatic function increases stiffness to drive colorectal cancer progression through FAK. *Oncogene*. 2013 Apr 4; 32(14):1863–8. [PubMed: 22641216]
85. Hajnal A, Klemenz R, Schafer R. Up-regulation of lysyl oxidase in spontaneous revertants of H-ras-transformed rat fibroblasts. *Cancer research*. 1993 Oct 1; 53(19):4670–5. [PubMed: 7691400]
86. Contente S, Kenyon K, Rimoldi D, Friedman RM. Expression of gene *rrg* is associated with reversion of NIH 3T3 transformed by LTR-c-H-ras. *Science*. 1990 Aug 17; 249(4970):796–8. [PubMed: 1697103]
- **87. Kenyon K, Contente S, Trackman PC, Tang J, Kagan HM, Friedman RM. Lysyl oxidase and *rrg* messenger RNA. *Science*. 1991 Aug 16; 253(5021):802. This paper connected lysyl oxidase expression with the maintenance of a normal phenotype in c-H-ras-transformed stable phenotypic revertants and identified lysyl oxidase as having tumor suppressor activity. [PubMed: 1678898]
88. Hamalainen ER, Kemppainen R, Kuivaniemi H, Tromp G, Vaheri A, Pihlajaniemi T, et al. Quantitative polymerase chain reaction of lysyl oxidase mRNA in malignant transformed human cell lines demonstrates that their low lysyl oxidase activity is due to low quantities of its mRNA and low levels of transcription of the respective gene. *The Journal of biological chemistry*. 1995 Sep 15; 270(37):21590–3. [PubMed: 7665572]
89. Kuivaniemi H, Korhonen RM, Vaheri A, Kivirikko KI. Deficient production of lysyl oxidase in cultures of malignant transformed human cells. *FEBS letters*. 1986 Jan 20; 195(1-2):261–4. [PubMed: 3753686]
- *90. Bais MV, Nugent MA, Stephens DN, Sume SS, Kirsch KH, Sonenshein GE, et al. Recombinant lysyl oxidase propeptide protein inhibits growth and promotes apoptosis of pre-existing murine breast cancer xenografts. *PloS one*. 2012; 7(2):e31188. A slow release formulation of recombinant lysyl oxidase propeptide protein was shown to inhibit the growth of breast cancer xenografts and supported the notion that the lysyl oxidase propeptide could have therapeutic potential. [PubMed: 22363577]
91. Ozdener GB, Bais MV, Trackman PC. Determination of cell uptake pathways for tumor inhibitor lysyl oxidase propeptide. *Molecular oncology*. 2016; 10(1):1–23. [PubMed: 26297052]
92. Agra N, Cidre F, Garcia-Garcia L, de la Parra J, Alonso J. Lysyl oxidase is downregulated by the EWS/FLI1 oncoprotein and its propeptide domain displays tumor suppressor activities in ewing sarcoma cells. *PloS one*. 2013; 8(6):e66281. [PubMed: 23750284]
- *93. Min C, Yu Z, Kirsch KH, Zhao Y, Vora SR, Trackman PC, et al. A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer. *Cancer research*. 2009 Aug 15; 69(16):6685–93. This paper provides experimental evidence that the lysyl oxidase propeptide is both a tumor suppressor and a tumor growth inhibitor. [PubMed: 19654310]
94. Ahn SG, Dong SM, Oshima A, Kim WH, Lee HM, Lee SA, et al. LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients. *Breast cancer research and treatment*. 2013 Aug; 141(1):89–99. [PubMed: 23933800]

95. Akiri G, Sabo E, Dafni H, Vadasz Z, Kartvelishvili Y, Gan N, et al. Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo. *Cancer research*. 2003 Apr 1; 63(7):1657–66. [PubMed: 12670920]
96. Barker HE, Bird D, Lang G, Erler JT. Tumor-secreted LOXL2 activates fibroblasts through FAK signaling. *Molecular cancer research : MCR*. 2013 Nov; 11(11):1425–36. [PubMed: 24008674]
97. Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. *Nature medicine*. 2010 Sep; 16(9):1009–17.
98. Canesin G, Cuevas EP, Santos V, Lopez-Menendez C, Moreno-Bueno G, Huang Y, et al. Lysyl oxidase-like 2 (LOXL2) and E47 EMT factor: novel partners in E-cadherin repression and early metastasis colonization. *Oncogene*. 2015 Feb 19; 34(8):951–64. [PubMed: 24632622]
99. Fukumoto I, Kikkawa N, Matsushita R, Kato M, Kurozumi A, Nishikawa R, et al. Tumor-suppressive microRNAs (miR-26a/b, miR-29a/b/c and miR-218) concertedly suppressed metastasis-promoting LOXL2 in head and neck squamous cell carcinoma. *Journal of human genetics*. 2015 Oct 22.doi: 10.1038/jhg.2015.120
100. Kasashima H, Yashiro M, Kinoshita H, Fukuoka T, Morisaki T, Masuda G, et al. Lysyl oxidase-like 2 (LOXL2) from stromal fibroblasts stimulates the progression of gastric cancer. *Cancer letters*. 2014 Nov 28; 354(2):438–46. [PubMed: 25128648]
101. Moon HJ, Finney J, Xu L, Moore D, Welch DR, Mure M. MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro. *The Journal of biological chemistry*. 2013 Oct 18; 288(42):30000–8. [PubMed: 24014025]
102. Moreno-Bueno G, Salvador F, Martin A, Floristan A, Cuevas EP, Santos V, et al. Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas. *EMBO molecular medicine*. 2011 Sep; 3(9):528–44. [PubMed: 21732535]
103. Peinado H, Moreno-Bueno G, Hardisson D, Perez-Gomez E, Santos V, Mendiola M, et al. Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas. *Cancer research*. 2008 Jun 15; 68(12):4541–50. [PubMed: 18559498]
104. Peng L, Ran YL, Hu H, Yu L, Liu Q, Zhou Z, et al. Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway. *Carcinogenesis*. 2009 Oct; 30(10):1660–9. [PubMed: 19625348]
105. Wong CC, Tse AP, Huang YP, Zhu YT, Chiu DK, Lai RK, et al. Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma. *Hepatology (Baltimore, Md)*. 2014 Nov; 60(5):1645–58.
106. Li RK, Zhao WY, Fang F, Zhuang C, Zhang XX, Yang XM, et al. Lysyl oxidase-like 4 (LOXL4) promotes proliferation and metastasis of gastric cancer via FAK/Src pathway. *Journal of cancer research and clinical oncology*. 2015 Feb; 141(2):269–81. [PubMed: 25216702]
107. Gorogh T, Weise JB, Holtmeier C, Rudolph P, Hedderich J, Gottschlich S, et al. Selective upregulation and amplification of the lysyl oxidase like-4 (LOXL4) gene in head and neck squamous cell carcinoma. *The Journal of pathology*. 2007 May; 212(1):74–82. [PubMed: 17354256]
108. Palamakumbura AH, Vora SR, Nugent MA, Kirsch KH, Sonenshein GE, Trackman PC. Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling. *Oncogene*. 2009 Sep 24; 28(38):3390–400. [PubMed: 19597471]
109. Vora SR, Palamakumbura AH, Mitsi M, Guo Y, Pischon N, Nugent MA, et al. Lysyl oxidase propeptide inhibits FGF-2-induced signaling and proliferation of osteoblasts. *The Journal of biological chemistry*. 2010 Mar 5; 285(10):7384–93. [PubMed: 20048148]
- *110. Bais MV, Ozdener GB, Sonenshein GE, Trackman PC. Effects of tumor-suppressor lysyl oxidase propeptide on prostate cancer xenograft growth and its direct interactions with DNA repair pathways. *Oncogene*. 2015 Apr 9; 34(15):1928–37. This paper demonstrates that nuclear lysyl oxidase propeptide interacts with the MRN complex in the nucleus and inhibits DNA repair, suggesting that LOX-PP could be used to enhance radiation-based therapeutic approaches. [PubMed: 24882580]

111. Zhao Y, Min C, Vora SR, Trackman PC, Sonenshein GE, Kirsch KH. The lysyl oxidase propeptide attenuates fibronectin-mediated activation of focal adhesion kinase and p130Cas in breast cancer cells. *The Journal of biological chemistry*. 2009 Jan 16; 284(3):1385–93. [PubMed: 19029090]
112. Sanchez-Morgan N, Kirsch KH, Trackman PC, Sonenshein GE. The lysyl oxidase propeptide interacts with the receptor-type protein tyrosine phosphatase kappa and inhibits beta-catenin transcriptional activity in lung cancer cells. *Molecular and cellular biology*. 2011 Aug; 31(16): 3286–97. [PubMed: 21690299]
113. Sato S, Trackman PC, Maki JM, Myllyharju J, Kirsch KH, Sonenshein GE. The Ras signaling inhibitor LOX-PP interacts with Hsp70 and c-Raf to reduce Erk activation and transformed phenotype of breast cancer cells. *Molecular and cellular biology*. 2011 Jul; 31(13):2683–95. [PubMed: 21536655]
114. Sato S, Zhao Y, Imai M, Simister PC, Feller SM, Trackman PC, et al. Inhibition of CIN85-Mediated Invasion by a Novel SH3 Domain Binding Motif in the Lysyl Oxidase Propeptide. *PloS one*. 2013; 8(10):e77288. [PubMed: 24167568]
115. Li J, Gu X, Ma Y, Calicchio ML, Kong D, Teng YD, et al. Nna1 mediates Purkinje cell dendritic development via lysyl oxidase propeptide and NF-kappaB signaling. *Neuron*. 2010 Oct 6; 68(1): 45–60. [PubMed: 20920790]
116. Jeay S, Pianetti S, Kagan HM, Sonenshein GE. Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B. *Molecular and cellular biology*. 2003 Apr; 23(7):2251–63. [PubMed: 12640111]
117. Liu X, Zhao Y, Gao J, Pawlyk B, Starcher B, Spencer JA, et al. Elastic fiber homeostasis requires lysyl oxidase-like 1 protein. *Nature genetics*. 2004 Feb; 36(2):178–82. [PubMed: 14745449]
118. Lee UJ, Gustilo-Ashby AM, Daneshgari F, Kuang M, Vurbic D, Lin DL, et al. Lower urogenital tract anatomical and functional phenotype in lysyl oxidase like-1 knockout mice resembles female pelvic floor dysfunction in humans. *American journal of physiology Renal physiology*. 2008 Aug; 295(2):F545–55. [PubMed: 18495804]
119. Liu X, Zhao Y, Pawlyk B, Damaser M, Li T. Failure of elastic fiber homeostasis leads to pelvic floor disorders. *The American journal of pathology*. 2006 Feb; 168(2):519–28. [PubMed: 16436666]
120. Wiggs JL, Pawlyk B, Connolly E, Adamian M, Miller JW, Pasquale LR, et al. Disruption of the blood-aqueous barrier and lens abnormalities in mice lacking lysyl oxidase-like 1 (LOXL1). *Investigative ophthalmology & visual science*. 2014 Feb; 55(2):856–64. [PubMed: 24425853]
121. Alsofi L, Daley E, Hornstra I, Morgan EF, Mason ZD, Acevedo JF, et al. Sex-Linked Skeletal Phenotype of Lysyl Oxidase Like-1 Mutant Mice. *Calcif Tissue Int*. 2015 Nov; 98(2):172–85. [PubMed: 26538021]
122. Thorleifsson G, Magnusson KP, Sulem P, Walters GB, Gudbjartsson DF, Stefansson H, et al. Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. *Science*. 2007 Sep 7; 317(5843):1397–400. [PubMed: 17690259]
123. Hewitt AW, Sharma S, Burdon KP, Wang JJ, Baird PN, Dimasi DP, et al. Ancestral LOXL1 variants are associated with pseudoexfoliation in Caucasian Australians but with markedly lower penetrance than in Nordic people. *Human molecular genetics*. 2008 Mar 1; 17(5):710–6. [PubMed: 18037624]
124. Anastasopoulos E, Founti P, Topouzis F. Update on pseudoexfoliation syndrome pathogenesis and associations with intraocular pressure, glaucoma and systemic diseases. *Current opinion in ophthalmology*. 2015 Mar; 26(2):82–9. [PubMed: 25594764]
125. Wiggs JL, Pasquale LR. Expression and regulation of LOXL1 and elastin-related genes in eyes with exfoliation syndrome. *Journal of glaucoma*. 2014 Oct-Nov; 23(8 Suppl 1):S62–3. [PubMed: 25275910]
126. Shearer TR, Anderson RS. Histologic changes during selenite cataractogenesis: a light microscopy study. *Experimental eye research*. 1985 Apr; 40(4):557–65. [PubMed: 4007070]
127. Wu G, Guo Z, Chang X, Kim MS, Nagpal JK, Liu J, et al. LOXL1 and LOXL4 are epigenetically silenced and can inhibit ras/extracellular signal-regulated kinase signaling pathway in human bladder cancer. *Cancer research*. 2007 May 1; 67(9):4123–9. [PubMed: 17456585]

128. Lee GH, Kim DS, Chung MJ, Chae SW, Kim HR, Chae HJ. Lysyl oxidase-like-1 enhances lung metastasis when lactate accumulation and monocarboxylate transporter expression are involved. *Oncology letters*. 2011 Sep 1; 2(5):831–38. [PubMed: 22866136]
129. Yang H, Rouse J, Lukes L, Lancaster M, Veenstra T, Zhou M, et al. Caffeine suppresses metastasis in a transgenic mouse model: a prototype molecule for prophylaxis of metastasis. *Clinical & experimental metastasis*. 2004; 21(8):719–35. [PubMed: 16035617]
130. Torres S, Garcia-Palmero I, Herrera M, Bartolome RA, Pena C, Fernandez-Acenero MJ, et al. LOXL2 Is Highly Expressed in Cancer-Associated Fibroblasts and Associates to Poor Colon Cancer Survival. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2015 Nov 1; 21(21):4892–902. [PubMed: 26206869]
131. Martin A, Salvador F, Moreno-Bueno G, Floristan A, Ruiz-Herguido C, Cuevas EP, et al. Lysyl oxidase-like 2 represses Notch1 expression in the skin to promote squamous cell carcinoma progression. *The EMBO journal*. 2015 Apr 15; 34(8):1090–109. [PubMed: 25759215]
132. Bais MV, Kukuruzinska M, Trackman PC. Orthotopic non-metastatic and metastatic oral cancer mouse models. *Oral oncology*. 2015 May; 51(5):476–82. [PubMed: 25682387]
133. Xu J, Li D, Li X, Liu Z, Li T, Jiang P, et al. 67 laminin receptor promotes the malignant potential of tumour cells up-regulating lysyl oxidase-like 2 expression in cholangiocarcinoma. *Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver*. 2014 Aug; 46(8):750–7.
134. Hollosi P, Yakushiji JK, Fong KS, Csiszar K, Fong SF. Lysyl oxidase-like 2 promotes migration in noninvasive breast cancer cells but not in normal breast epithelial cells. *International journal of cancer Journal international du cancer*. 2009 Jul 15; 125(2):318–27. [PubMed: 19330836]
135. Moreno-Bueno G, Salvador F, Martín A, Floristán A, Cuevas EP, Santos V, et al. Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas. *EMBO molecular medicine*. 2011 Sep; 3(9):528–44. [PubMed: 21732535]
136. Zhan P, Shen XK, Qian Q, Zhu JP, Zhang Y, Xie HY, et al. Down-regulation of lysyl oxidase-like 2 (LOXL2) is associated with disease progression in lung adenocarcinomas. *Medical oncology (Northwood, London, England)*. 2012 Jun; 29(2):648–55.
137. Nishikawa R, Chiyomaru T, Enokida H, Inoguchi S, Ishihara T, Matsushita R, et al. Tumour-suppressive microRNA-29s directly regulate LOXL2 expression and inhibit cancer cell migration and invasion in renal cell carcinoma. *FEBS letters*. 2015 Jul 22; 589(16):2136–45. [PubMed: 26096783]
138. Mizuno K, Seki N, Mataka H, Matsushita R, Kamikawaji K, Kumamoto T, et al. Tumor-suppressive microRNA-29 family inhibits cancer cell migration and invasion directly targeting LOXL2 in lung squamous cell carcinoma. *International journal of oncology*. 2016 Feb; 48(2):450–60. [PubMed: 26676674]
139. Schietke R, Warnecke C, Wacker I, Schodel J, Mole DR, Campean V, et al. The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights into cellular transformation processes mediated by HIF-1. *The Journal of biological chemistry*. 2010 Feb 26; 285(9):6658–69. [PubMed: 20026874]
140. McCready J, Wong DS, Burlison JA, Ying W, Jay DG. An Impermeant Ganetespib Analog Inhibits Extracellular Hsp90-Mediated Cancer Cell Migration that Involves Lysyl Oxidase 2-like Protein. *Cancers*. 2014; 6(2):1031–46. [PubMed: 24785146]
- *141. Peinado H, del Carmen Iglesias-de la Cruz M, Olmeda D, Csiszar K, Fong KSK, Vega S, et al. A molecular role for lysyl oxidase-like 2 enzyme in Snail regulation and tumor progression. *The EMBO journal*. 2005 Aug 18; 24(19):3446–58. Evidence was presented for a direct interaction of LOXL2 with Snail to promote epithelial to mesenchymal transition. [PubMed: 16096638]
- *142. Cuevas EP, Moreno-Bueno G, Canesin G, Santos V, Portillo F, Cano A. LOXL2 catalytically inactive mutants mediate epithelial-to-mesenchymal transition. *Biology open*. 2014; 3(2):129–37. The effect of LOXL2 on repression of cell adhesion receptors E-cadherin, claudin and Lgl2 in its stimulation of EMT does not required LOXL2 enzyme activity. [PubMed: 24414204]
143. Lv GQ, Zou HY, Liao LD, Cao HH, Zeng FM, Wu BL, et al. Identification of a novel lysyl oxidase-like 2 alternative splicing isoform, LOXL2 Deltae13, in esophageal squamous cell

carcinoma. *Biochemistry and cell biology = Biochimie et biologie cellulaire*. 2014 Oct; 92(5): 379–89. [PubMed: 25275797]

144. Iturbide A, Garcia de Herreros A, Peiro S. A new role for LOX and LOXL2 proteins in transcription regulation. *The FEBS journal*. 2015 May; 282(9):1768–73. [PubMed: 25103872]
145. Iturbide A, Pascual-Reguant L, Fargas L, Cebria JP, Alsina B, Garcia de Herreros A, et al. LOXL2 Oxidizes Methylated TAF10 and Controls TFIID-Dependent Genes during Neural Progenitor Differentiation. *Molecular cell*. 2015 Jun 4; 58(5):755–66. [PubMed: 25959397]
146. Millanes-Romero A, Herranz N, Perrera V, Iturbide A, Loubat-Casanovas J, Gil J, et al. Regulation of heterochromatin transcription by Snail1/LOXL2 during epithelial-to-mesenchymal transition. *Molecular cell*. 2013 Dec 12; 52(5):746–57. [PubMed: 24239292]
147. Herranz N, Dave N, Millanes-Romero A, Morey L, Diaz VM, Lorenz-Fonfria V, et al. Lysyl oxidase-like 2 deaminates lysine 4 in histone H3. *Molecular cell*. 2012 May 11; 46(3):369–76. [PubMed: 22483618]
148. Bignon M, Pichol-Thievend C, Hardouin J, Malbouyres M, Bréchet N, Nasciutti L, et al. Lysyl oxidase-like protein-2 regulates sprouting angiogenesis and type IV collagen assembly in the endothelial basement membrane. *Blood*. 2011 Oct 06; 118(14):3979–89. [PubMed: 21835952]
149. Zaffryar-Eilot S, Marshall D, Voloshin T, Bar-Zion A, Spangler R, Kessler O, et al. Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours. *Carcinogenesis*. 2013 Oct; 34(10):2370–9. [PubMed: 23828904]
150. Hong HH, Pischon N, Santana RB, Palamakumbura AH, Chase HB, Gantz D, et al. A role for lysyl oxidase regulation in the control of normal collagen deposition in differentiating osteoblast cultures. *Journal of cellular physiology*. 2004 Jul; 200(1):53–62. [PubMed: 15137057]
151. Kim JH, Lee EH, Park HJ, Park EK, Kwon TG, Shin HI, et al. The role of lysyl oxidase-like 2 in the odontogenic differentiation of human dental pulp stem cells. *Molecules and cells*. 2013 Jun; 35(6):543–9. [PubMed: 23677379]
152. Shibata Y, Suzuki D, Wurihan, Yamada A, Maruyama N, Fujisawa N, et al. Lysyl oxidase like-2 reinforces unsatisfactory ossification induced by bone morphogenetic protein-2: relating nanomechanical properties and molecular changes. *Nanomedicine : nanotechnology, biology, and medicine*. 2013 Oct; 9(7):1036–47.
153. Zhang J, Yang R, Liu Z, Hou C, Zong W, Zhang A, et al. Loss of lysyl oxidase-like 3 causes cleft palate and spinal deformity in mice. *Human molecular genetics*. 2015 Nov 1; 24(21):6174–85. [PubMed: 26307084]
154. Alzahrani F, Al Hazzaa SA, Tayeb H, Alkuraya FS. LOXL3, encoding lysyl oxidase-like 3, is mutated in a family with autosomal recessive Stickler syndrome. *Human genetics*. 2015 Apr; 134(4):451–3. [PubMed: 25663169]
155. Jourdan-Le Saux C, Tomsche A, Ujfalusi A, Jia L, Csiszar K. Central nervous system, uterus, heart, and leukocyte expression of the LOXL3 gene, encoding a novel lysyl oxidase-like protein. *Genomics*. 2001 Jun 1; 74(2):211–8. [PubMed: 11386757]
156. Lee JE, Kim Y. A tissue-specific variant of the human lysyl oxidase-like protein 3 (LOXL3) functions as an amine oxidase with substrate specificity. *The Journal of biological chemistry*. 2006 Dec 8; 281(49):37282–90. [PubMed: 17018530]
157. Busnadiego O, Gonzalez-Santamaria J, Lagares D, Guinea-Viniegra J, Pichol-Thievend C, Muller L, et al. LOXL4 is induced by transforming growth factor beta1 through Smad and JunB/Fra2 and contributes to vascular matrix remodeling. *Molecular and cellular biology*. 2013 Jun; 33(12): 2388–401. [PubMed: 23572561]
158. Sebban S, Golan-Gerstl R, Karni R, Vaksman O, Davidson B, Reich R. Alternatively spliced lysyl oxidase-like 4 isoforms have a pro-metastatic role in cancer. *Clinical & experimental metastasis*. 2013 Jan; 30(1):103–17. [PubMed: 22806361]
159. Sebban S, Davidson B, Reich R. Lysyl oxidase-like 4 is alternatively spliced in an anatomic site-specific manner in tumors involving the serosal cavities. *Virchows Archiv : an international journal of pathology*. 2009 Jan; 454(1):71–9. [PubMed: 19015874]
160. Scola N, Gorogh T. LOXL4 as a selective molecular marker in primary and metastatic head/neck carcinoma. *Anticancer Res*. 2010 Nov; 30(11):4567–71. [PubMed: 21115907]

161. Yilmaz M, Suer I, Karatas OF, Cansiz H, Ozen M. Differential Expression of LOXL4 in Normal and Tumor Tissue Samples of Laryngeal Squamous Cell Carcinoma. *Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery*. 2015 Jul 2;doi: 10.1111/coa.12498.
162. Gorogh T, Holtmeier C, Weise JB, Hoffmann M, Ambrosch P, Laudien M, et al. Functional analysis of the 5' flanking domain of the LOXL4 gene in head and neck squamous cell carcinoma cells. *International journal of oncology*. 2008 Nov; 33(5):1091–8. [PubMed: 18949373]
163. Tang SS, Chichester CO, Kagan HM. Comparative sensitivities of purified preparations of lysyl oxidase and other amine oxidases to active site-directed enzyme inhibitors. *Connective tissue research*. 1989; 19(1):93–103. [PubMed: 2571459]
164. Tang SS, Trackman PC, Kagan HM. Reaction of aortic lysyl oxidase with beta-aminopropionitrile. *The Journal of biological chemistry*. 1983 Apr 10; 258(7):4331–8. [PubMed: 6131892]
165. Ovet H, Oztay F. The copper chelator tetrathiomolybdate regressed bleomycin-induced pulmonary fibrosis in mice, by reducing lysyl oxidase expressions. *Biological trace element research*. 2014 Dec; 162(1-3):189–99. [PubMed: 25349139]
166. Kumar P, Yadav A, Patel SN, Islam M, Pan Q, Merajver SD, et al. Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis. *Molecular cancer*. 2010; 9:206. [PubMed: 20682068]
167. Kwang Kim K, Abelman S, Yano N, Ribeiro JR, Singh RK, Tipping M, et al. Tetrathiomolybdate inhibits mitochondrial complex IV and mediates degradation of hypoxia-inducible factor-1alpha in cancer cells. *Scientific reports*. 2015; 5:14296. [PubMed: 26469226]
168. Wilson DF, Vinogradov SA. Mitochondrial cytochrome c oxidase: mechanism of action and role in regulating oxidative phosphorylation. *Journal of applied physiology (Bethesda, Md : 1985)*. 2014 Dec 15; 117(12):1431–9.
169. Heidi S, Alberto B, Terrie-Anne C, Mandar D, Alison DF, Jonathan SF, et al. Inhibition Of LOXL2: Pharmaxis' Small Molecule Approach To Treat Fibrosis. *C30 Late Breaking Abstracts In Disease Treatment and Clinical Outcomes*. American Thoracic Society. 2014:A6669–A69.
170. Schilter H, Buson A, Cock TA, Deodhar M, Findlay AD, Foot JS, et al. Inhibition of LOXL2: Pharmaxis' small molecule approach to treat fibrosis. *Am J Respir Crit Care Med*. 2014; 189:A6669.
171. Miller BW, Morton JP, Pinese M, Saturno G, Jamieson NB, McGhee E, et al. Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. *EMBO molecular medicine*. 2015 Aug; 7(8):1063–76. [PubMed: 26077591]
172. Alsulaiman M, Bais MV, Trackman PC. Lysyl oxidase propeptide stimulates osteoblast and osteoclast differentiation and enhances PC3 and DU145 prostate cancer cell effects on bone in vivo. *Journal of cell communication and signaling*. 2015 Dec 1. Epub ahead of print.
173. Barker HE, Cox TR, Erler JT. The rationale for targeting the LOX family in cancer. *Nature reviews Cancer*. 2012 Aug; 12(8):540–52. [PubMed: 22810810]

Article highlights box

- Dysregulation of lysyl oxidases is linked to fibrosis and cancer in a variety of tissues and organs.
- The lysyl oxidase family of proteins consists of five members and is required for normal biosynthesis of the extracellular matrix.
- Functions of the lysyl oxidase family of proteins extend beyond the classically known contributions to collagen and elastin cross-linking and include regulation of cell proliferation and differentiation.
- Respective unique domains of lysyl oxidase family members mediate novel functions and some of these are independent of active lysyl oxidase enzyme activity.
- The current understanding of contributions of both enzyme-dependent and non-enzyme dependent activities of lysyl oxidases to fibrosis and cancer points to the high likelihood of future development of potential therapeutic opportunities. Such opportunities will grow out of an increased mechanistic understanding of the variety of functions of the versatile lysyl oxidase family.

Figure 1.
The mechanism of action of the lysyl oxidase-catalyzed reaction ²⁶. The red molecule represents the primary amine substrate or lysine side chain substrate. The numbers identify the sequence of the reaction steps.